checkmate 743 shows that dual immunotherapy, nivolumab + ipilimumab

(International Association for the Study of Lung Cancer) The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium.